To measure the effect of Ivermectin (sub-cutaneous) with or without zinc in treating the COVID-19 patients to clear viral load of SARS-CoV-2 along with reduction in severity of symptoms and length of hospitalization of patients with COVID-19.
This is a parallel assigned, randomized, controlled, multi-armed, investigator Initiated
interventional study is designed to demonstrate efficacy to lower the viral load of COVID-19
and to demonstrate the antiviral effects of subcutaneous Ivermectin with or without zinc in
mild to moderate symptomatic patients who consent to randomization following a new diagnosis
in Pakistan with COVID-19 (PCR positive). Investigators will follow up with participants
daily and PCR will be done on alternate days in BSL-3 lab. Dose will only be repeated if test
remained positive..
Drug: Ivermectin Injectable Solution
Subcutaneous Ivermectin 200ug/kg body weight 48 hourly
Other Name: Montpellier
Other: Injectable Placebo
0.9% normal saline
Other Name: 0.9% normal saline
Drug: Zinc
Zinc Sulphate 20mg 3 times a day
Drug: Placebo empty capsule
Placebo empty capsule
Drug: Oral Ivermectin
0.2mg/kg/day
Inclusion Criteria:
- Nasopharyngeal RT-PCR positive SARS-CoV-2 patient with mild to moderate disease
- Age 18 and above
- BMI 18-28 kg/m
Exclusion Criteria:
- Allergy to any drug
- Co-morbidities: any pre-existing cardiac disease, pulmonary disease
- Arrhythmias
- Pregnancy
- RT-PCR performed >3 days prior to enrollment
Ali Clinic
Lahore, MA, Pakistan
Shaikh Zayed Hospital
Lahore, Punjab, Pakistan
Sohaib Ashraf, MBBS
+923334474523
sohaib-ashraf@outlook.com
Shoaib Ashraf, PhD
+16177949579
sashraf@mgh.harvard.edu